Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Genecapture Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner and 1 distinct art unit. The company's current prosecution activity is focused on this single technical domain. Practitioners should analyze the specific allowance rates and trends of this 1 distinct art unit to optimize their response strategy. The concentration of the portfolio suggests that the company is focusing its intellectual property efforts on a specific biological or pharmaceutical innovation. This allows for a high degree of attention to the details of the pending matter.
The busiest examiner for the portfolio is TURPIN, ZACHARY MARK, who is currently managing 1 pending office action. This represents the total number of pending office actions for the company. Having 1 distinct examiner and 1 distinct art unit means that the prosecution process is centralized. This allows for a targeted approach when addressing the requirements of the patent office. The workload of 1 busiest examiner pending 1 matter indicates that the company is currently focused on a single active application. This streamlined prosecution environment reduces the complexity of managing multiple examiner interviews or conflicting art unit requirements.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TURPIN, ZACHARY MARK | 1 | 4.0% | -5.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18358551 | COMPOSITIONS, METHODS AND DEVICES COMPRISING STEM-LOOP CAPTOR MOLECULES | TURPIN, ZACHARY MARK | — |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18358551 | COMPOSITIONS, METHODS AND DEVICES COMPRISING STEM-LOOP CAPTOR MOLECULES | TURPIN, ZACHARY MARK | 1682 | §101§102§103§112DP | Non-Final OA | — | Pending | Jul 25, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial